R
Rebecca J. Nagy
Researcher at Samsung Medical Center
Publications - 89
Citations - 4680
Rebecca J. Nagy is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 31, co-authored 88 publications receiving 2869 citations.
Papers
More filters
Journal ArticleDOI
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Zofia Piotrowska,Hideko Isozaki,Jochen K. Lennerz,Justin F. Gainor,Inga T. Lennes,Viola W. Zhu,Nicolas Marcoux,Mandeep Banwait,Subba R. Digumarthy,Wenjia Su,Satoshi Yoda,Amanda K. Riley,Varuna Nangia,Jessica J. Lin,Rebecca J. Nagy,Richard B. Lanman,Dora Dias-Santagata,Mari Mino-Kenudson,A. John Iafrate,Rebecca S. Heist,Alice T. Shaw,Erica Evans,Corinne Clifford,Sai-Hong Ignatius Ou,Beni B. Wolf,Aaron N. Hata,Lecia V. Sequist +26 more
TL;DR: Proof of concept that RET fusions can mediate acquired resistance to EGFR TKIs and that combined EGFR and RET inhibition with osimertinib/BLU-667 may be a well-tolerated and effective treatment strategy for such patients are provided.
Journal ArticleDOI
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- And Plasma-Based Methodologies
Justin I. Odegaard,John J. Vincent,Stefanie Mortimer,James V. Vowles,Bryan C. Ulrich,Kimberly C. Banks,Stephen R. Fairclough,Oliver A. Zill,Marcin Sikora,Reza Bayat Mokhtari,Diana Abdueva,Rebecca J. Nagy,Christine E. Lee,Lesli A. Kiedrowski,Cloud P. Paweletz,Helmy Eltoukhy,Richard B. Lanman,Darya Chudova,AmirAli Talasaz +18 more
TL;DR: High concordance with orthogonal clinical plasma- and tissue-based genotyping methods supports the clinical accuracy of digital sequencing across all four types of targetable genomic alterations.
Journal ArticleDOI
The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients
Oliver A. Zill,Kimberly C. Banks,Stephen R. Fairclough,Stefanie Mortimer,James V. Vowles,Reza Mokhtari,David R. Gandara,Philip C. Mack,Justin I. Odegaard,Rebecca J. Nagy,Arthur Baca,Helmy Eltoukhy,Darya Chudova,Richard B. Lanman,AmirAli Talasaz +14 more
TL;DR: Together, these retrospective analyses of a large cfDNA sequencing data set reveal subclonal structures and emerging resistance in advanced solid tumors.
Journal ArticleDOI
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
R. Condorelli,Laura Spring,Joyce O'Shaughnessy,Ludovic Lacroix,Caroline Bailleux,Véronique Scott,J. Dubois,Rebecca J. Nagy,Richard B. Lanman,Anthony J. Iafrate,Fabrice Andre,Aditya Bardia +11 more
TL;DR: This is the first clinical report to describe the emergence of somatic RB1 mutations after exposure to palbociclib or ribocic lib, in patients with metastatic breast cancer.
Journal ArticleDOI
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Luigi Formisano,Yao Lu,Alberto Servetto,Ariella B. Hanker,Ariella B. Hanker,Valerie M. Jansen,Joshua A. Bauer,Dhivya R. Sudhan,Dhivya R. Sudhan,Angel Guerrero-Zotano,Sarah Croessmann,Yan Guo,Paula Gonzalez Ericsson,Kyungmin Lee,Mellissa J. Nixon,Luis J. Schwarz,Melinda E. Sanders,Teresa C. Dugger,Marcelo Rocha Cruz,Amir Behdad,Massimo Cristofanilli,Aditya Bardia,Joyce O'Shaughnessy,Rebecca J. Nagy,Richard B. Lanman,Nadia Solovieff,Wei He,Michelle Miller,Fei Su,Yu Shyr,Ingrid A. Mayer,Justin M. Balko,Carlos L. Arteaga,Carlos L. Arteaga +33 more
TL;DR: It is shown that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK 4/6, and anti-estrogens is a potential therapeutic strategy in Era+ breast cancer tumors.